477 related articles for article (PubMed ID: 30353552)
1. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
Ampuero J; Aller R; Gallego-Durán R; Banales JM; Crespo J; García-Monzón C; Pareja MJ; Vilar-Gómez E; Caballería J; Escudero-García D; Gomez-Camarero J; Calleja JL; Latorre M; Albillos A; Salmeron J; Aspichueta P; Lo Iacono O; Francés R; Benlloch S; Fernández-Rodríguez C; García-Samaniego J; Estévez P; Andrade RJ; Turnes J; Romero-Gómez M;
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1260-1270. PubMed ID: 30353552
[TBL] [Abstract][Full Text] [Related]
2. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
3. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
[TBL] [Abstract][Full Text] [Related]
4. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status.
Huh JH; Kim KJ; Kim SU; Han SH; Han KH; Cha BS; Chung CH; Lee BW
Metabolism; 2017 Jan; 66():23-31. PubMed ID: 27923446
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.
Lonardo A; Mantovani A; Lugari S; Targher G
Ann Hepatol; 2020; 19(4):359-366. PubMed ID: 32349939
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease Severity Is Related to Plasma Pro-Oxidative Biomarkers Rather Than Liver Tissue-Measured Nitrogen Metabolism Biomarkers in Population with Obesity and Metabolic Syndrome.
Suárez-Cuenca JA; Domínguez-Pérez GA; Hernández-Muñóz RE; Hernández-Patricio A; Vera-Gómez E; Gutiérrez-Buendía JA; Salamanca-García M; Montoya-Ramírez J; Gaytán-Fuentes OF; Aranda-Rodríguez C; Rojas-Noverón AR; García S; Mondragón-Terán P
Metab Syndr Relat Disord; 2023 Mar; 21(2):115-121. PubMed ID: 36787445
[No Abstract] [Full Text] [Related]
7. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.
Qureshi K; Abrams GA
Clin Obes; 2016 Apr; 6(2):117-23. PubMed ID: 26856683
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndrome.
Kim JY; Tfayli H; Michaliszyn SF; Lee S; Arslanian S
Fertil Steril; 2016 Jun; 105(6):1603-11. PubMed ID: 26921624
[TBL] [Abstract][Full Text] [Related]
9. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
[TBL] [Abstract][Full Text] [Related]
12. Insulin Resistance Is the Main Characteristic of Metabolically Unhealthy Obesity (MUO) Associated with NASH in Patients Undergoing Bariatric Surgery.
Schmitz SM; Storms S; Koch A; Stier C; Kroh A; Rheinwalt KP; Schipper S; Hamesch K; Ulmer TF; Neumann UP; Alizai PH
Biomedicines; 2023 May; 11(6):. PubMed ID: 37371690
[TBL] [Abstract][Full Text] [Related]
13. [Non-alcoholic fatty liver disease (NAFLD)].
Rau M; Weiss J; Geier A
Dtsch Med Wochenschr; 2015 Jul; 140(14):1051-5. PubMed ID: 26182253
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
[TBL] [Abstract][Full Text] [Related]
16. The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study.
Kouvari M; Chrysohoou C; Skoumas J; Pitsavos C; Panagiotakos DB; Mantzoros CS;
Metabolism; 2022 Mar; 128():154893. PubMed ID: 34600906
[TBL] [Abstract][Full Text] [Related]
17. Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk.
Du T; Yu X; Yuan G; Zhang J; Sun X
Cardiovasc Diabetol; 2015 Oct; 14():144. PubMed ID: 26511621
[TBL] [Abstract][Full Text] [Related]
18. Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study.
Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Najafipour F; Mobasseri M; Ostadrahimi A
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101754. PubMed ID: 34303827
[TBL] [Abstract][Full Text] [Related]
19. Less liver fibrosis in metabolically healthy compared with metabolically unhealthy obese patients with non-alcoholic fatty liver disease.
Gutiérrez-Grobe Y; Juárez-Hernández E; Sánchez-Jiménez BA; Uribe-Ramos MH; Ramos-Ostos MH; Uribe M; Chávez-Tapia NC
Diabetes Metab; 2017 Sep; 43(4):332-337. PubMed ID: 28318912
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
